Posted by The global Cyclodextrins in Pharmaceutical Market market stood at USD 1.2 billion in 2024 and is forecasted to achieve USD 2.5 billion by 2033, growing steadily at a CAGR of 9.2% from 2026 to 2033.
Furthermore, the market for cyclodextrins in pharmaceuticals is expanding due to increasing research into their potential in gene therapy and personalized medicine. The ability of cyclodextrins to encapsulate and protect sensitive biologic compounds makes them ideal candidates for such applications. The pharmaceutical industry is also witnessing growing interest in the development of innovative dosage forms, such as cyclodextrin-based nanoparticles, to improve therapeutic outcomes. As the market evolves, companies are exploring various types of cyclodextrins, such as hydroxypropyl-β-cyclodextrin (HPβCD), which is gaining popularity for its ability to enhance the solubility of drugs. For more detailed information on the trends and outlook in this sector, visit this [link](https://www.verifiedmarketreports.com/product/cyclodextrins-market/).
Major players operating in the Cyclodextrins in Pharmaceutical Market are:
- Ashland
- Cambrex Corporation
- Cayman Chemical
- Cyclo Therapeutics
- Ligand Pharmaceuticals Incorporated
- Merck KGaA
- Midas Pharma GmbH
- Otto Chemie
- TCI Chemicals
- VIO CHEMICALS
- Wacker Chemie AG
- Wellona Pharma